Johanna Olweus
@jolweus
Group leader & Head of Dept of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital; Professor, Inst. for Clin. Med., University of Oslo
ID: 901748071712923648
https://www.ous-research.no/olweus/ 27-08-2017 10:07:48
147 Tweet
520 Takipçi
106 Takip Edilen
We are inviting submissions for our Special Issue on Developments in Cell Therapy ESMO IOTECH . Submission deadline: 8 March 2024. Find out more and submit your manuscript ➡️ spkl.io/60154sUYl ESMO IOTECH
Fantastisk å være en del av MATCHMAKERS team og få et Cancer Grand Challenge Grant til Norden for første gang. Tusen takk til alle støttespillere! Kreftforeningen, Precision Immunotherapy Alliance Norges forskningsråd Oslounivsykehus UiO - Det medisinske fakultet Helse Sør-Øst RHF
We are grateful to our excellent SAB for their valuable advice! And to Ron Germain for sharing his spectacular data with us in Oslo Norges forskningsråd UiO - Det medisinske fakultet Oslounivsykehus
Join us at #ImmunoOnco24 and follow the inspiring talk of Johanna Olweus Johanna Olweus UiO - Medisinsk bibliotek! 🗓️Early bird registration till 18th of April vibconferences.be/events/recent-… CCB_VIB_KUL VIB Conferences
Happy to share that our great collaboration with Cinzia Cantacessi 🇪🇺🇮🇹🇦🇺🇬🇧 has led to a new research article on #nematode-derived #antimicrobial #peptides: csbj.org/article/S2001-… Thanks to James Rooney for his hard work during his PhD and for his exchange with us at DTU Bioengineering!
Great 1st session at the #CIMT2024 on Improving Immunity by leveraging Dendritic Cells (Stefani Spranger Koch Institute at MIT), rewiring microbiome (Marcel van den Brink City of Hope) and remodeling tumor vasculature (DimbergLab Uppsala University) to enhance Cancer #Immunotherapy Cancer Immunotherapy 🩸🧬🦠
Insightful #CIMT2024 session on Tumor Microenvironment and the complex cross-talk between dysregulated myeloid cells (Leila Akkari Karin de Visser The Netherlands Cancer Institute) and dendritic cells (Boettcher Lab TU München) at single cell and spatial level for #cancer prognosis and #immunotherapy
#CIMT2024 session in Advancing antibodies: Pushing forward technology for #cancer #immunotherapy via BiSpecific Abs (dimitris skokos Regeneron) Hexamerization-enhanced Abs (@estherbreij Genmab BioNTech SE) and BiSpec Abs targeting neutrophils marjolein van egmond Amsterdam UMC
Interesting panel debate on the role of excellent research in Norway and Europe - European Research Council (ERC) visiting Universitetet i Bergen
Now LIVE: the inaugural "Biology and Therapy of Myeloid Malignancies Conference" Fusion Conferences taking place May 14-17, 2025 on a beautiful Minoan coast in Crete, Greece. Huge thanks to co-organizer Ross Levine (and Lee Grimes Lab) ! #MyeloidMalignancies25 fusion-conferences.com/conference/180